Aspira Women’s Health (NASDAQ:AWH – Get Free Report) is anticipated to post its earnings results before the market opens on Thursday, March 27th. Analysts expect Aspira Women’s Health to post earnings of ($0.21) per share and revenue of $3.00 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Aspira Women’s Health Price Performance
NASDAQ AWH opened at $0.09 on Tuesday. The company has a fifty day moving average of $0.28 and a two-hundred day moving average of $0.62. The company has a market capitalization of $1.67 million, a PE ratio of -0.08 and a beta of 1.57. Aspira Women’s Health has a 1 year low of $0.08 and a 1 year high of $3.75.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on Aspira Women’s Health in a research report on Sunday, January 12th. They issued a “hold” rating for the company.
Aspira Women’s Health Company Profile
Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Recommended Stories
- Five stocks we like better than Aspira Women’s Health
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- What is MarketRank™? How to Use it
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- What is a Bond Market Holiday? How to Invest and Trade
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.
